Nanobiotix (Nasdaq:NBTX) - Stock Price, News & Analysis

NBTX Stock Overview

A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details

NBTX fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 93.5% below our estimate of its fair value

Risk Analysis

Negative shareholders equity

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Nanobiotix S.A. Competitors

Vaxart

NasdaqCM:VXRT

US$136.3m

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$162.8m

Compugen

NasdaqCM:CGEN

US$129.8m

Ocugen

NasdaqCM:OCGN

US$262.5m

Price History & Performance

Summary of all time highs, changes and price drops for Nanobiotix
Historical stock prices
Current Share Price	€3.79
52 Week High	€8.96
52 Week Low	€3.57
Beta	1.4
11 Month Change	-23.62%
3 Month Change	-28.25%
1 Year Change	-33.42%
33 Year Change	-55.11%
5 Year Change	n/a
Change since IPO	-77.69%

Recent updates

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Oct 18

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Sep 28

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Sep 12

Shareholder Returns

	NBTX	US Biotechs	US Market
7D	-3.6%	-3.7%	0.3%
1Y	-33.4%	15.2%	31.1%

Return vs Industry: NBTX underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: NBTX underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is NBTX's price volatile compared to industry and market?
NBTX volatility
NBTX Average Weekly Movement	9.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NBTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NBTX's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	110	Laurent Levy	www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. Fundamentals Summary

How do Nanobiotix's earnings and revenue compare to its market cap?
NBTX fundamental statistics
Market cap	US$172.78m
Earnings (TTM)	-US$34.86m
Revenue (TTM)	US$43.95m

3.9x

P/S Ratio

-5.0x

P/E Ratio

Is NBTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBTX income statement (TTM)
Revenue	€42.20m
Cost of Revenue	€0
Gross Profit	€42.20m
Other Expenses	€75.68m
Earnings	-€33.47m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.71
Gross Margin	100.00%
Net Profit Margin	-79.31%
Debt/Equity Ratio	-204.3%

How did NBTX perform over the long term?

See historical performance and comparison

NBTX Stock Overview

Rewards

Risk Analysis

Nanobiotix S.A. Competitors

NasdaqCM:VXRT

US$136.3m

NasdaqGS:ADAP

US$162.8m

NasdaqCM:CGEN

US$129.8m

NasdaqCM:OCGN

US$262.5m

Price History & Performance

Recent News & Updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix names Bart Van Rhijn as chief financial officer

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

Nanobiotix Will Disrupt Oncological Radiotherapy

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021